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Abstract
We describe the unprecedented formation of six ansamitocin derivatives that are deoxygenated at C-7 of the ansamitocin core,
obtained during fermentation experiments by employing a variety of Actinosynnema pretiosum mutants and mutasynthetic
approaches. We suggest that the formation of these derivatives is based on elimination at C-7/C-8 followed by reduction(s) of the
intermediate enone. In bioactivity tests, only ansamitocin derivatives bearing an ester side chain at C-3 showed strong
antiproliferative activity.
Introduction
Natural products still play an important role as lead structures
for the treatment of infectious diseases and cancer. However,
natural products have lost some of their attraction for the devel-
opment of pharmaceuticals because of their structural
complexity and the difficulties associated with accessing
analogues for structure–activity relationship studies. Total syn-
thesis approaches are still a tour de force and are hardly
employed, while commonly semisynthesis as well as biotechno-
logical approaches are widely pursued in industrial research
[1-3]. Investigations into the biosynthesis of natural products
have not only allowed us to understand the synthetic principles
that nature pursues, but have also provided tools, mainly based
on genetic engineering, which can be exploited in natural prod-
uct synthesis [4].
Producer strains genetically blocked in the biosynthesis of
important and complex natural products can serve as such new
tools. The synthetic concept based on these blocked mutants is
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Scheme 1: Summary of ansamitocin biosynthesis and structure of the related ansamycin antibiotic geldanamycin (6).
termed “mutational biosynthesis”, or in short mutasynthesis,
and it relies on the cellular uptake of modified biosynthetic
intermediates, sometimes termed mutasynthons, and their
incorporation into complex secondary metabolites [5-7].
When making use of mutants that are blocked in early stages of
a given biosynthesis pathway, the concept of mutasynthesis
may be compared to a (partial) natural product total synthesis.
When further modification of an advanced biosynthetic inter-
mediate with an established core structure towards bioactive
natural products and analogues is conducted, mutasynthesis
may be regarded as the “endgame” of a total synthesis [4].
The ansamitocins (maytansinoids) 3–5 are ideally suited for
mutasynthetic modifications and the creation of new analogues
because they are highly potent antitumor active compounds that
inhibit the growth of different leukemia cell lines as well as
human solid tumors at very low concentrations (10−3 to
10−7 µg/mL) [8]. In contrast to colchicine, maytansinoids such
as ansamitocins bind to β-tubulin monomers at a site overlap-
ping the vinca alkaloid binding site [9].
Recently, we disclosed several mutasynthetic studies aimed at
the production of derivatives of ansamitocins 3–5 [10-12] as
well as of geldanamycin (6), utilizing mutant strains of
Actinosynnema pretiosum, the ansamitocin producer [13-17],
and Streptomyces hygroscopicus, the geldanamycin producer
[18,19]. These engineered strains are unable to biosynthesize
3-amino-5-hydroxybenzoic acid (1) [20], the common starter
unit for both polyketide synthases (PKS) (Scheme 1). These
assembly-line-type multienzymes are responsible for setting up
the complete carbon backbone of both ansamycin antibiotics
[21-24].
More precisely, the biosynthesis of ansamitocins relies on a
type I modular polyketide synthase (PKS), with 3-amino-5-
hydroxybenzoic acid (1, AHBA) [20] as the starter unit fol-
lowed by chain extension by one “glycolate”, three propionate
and three acetate units. The last PKS module holds seco-
proansamitocin, which is released and cyclized, presumably by
an ansamycin amide synthase (Asm9) [21-24], to yield the
19-membered macrocyclic lactam proansamitocin (2).
Proansamitocin (2) is transformed into bioactive compounds
3–5 by a set of post-PKS tailoring steps, following a predeter-
mined, only partly flexible logic (Scheme 1) [16].
Complementing our studies with mutant strain A. pretiosum
HGF073, blocked in the biosynthesis of the PKS starter unit
AHBA 1 [13-16], we recently reported the use of a mutant of
A. pretiosum blocked in Asm12 (chlorination) and Asm21
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Figure 1: Fermentation products, proansamitocin (2) and derivatives 7–9, of the Asm12 and Asm21-blocked (chlorination, carbamoylation) mutant
strain A. pretiosum Δasm12/21 (yields given as isolated product per volume of fermentation broth) [17].
(carbamoylation) and therefore producing proansamitocin (2) in
good yield (up to 106 mg/L of fermentation broth) [17]. Addi-
tionally, we isolated small amounts of O-methyl proansami-
tocin 7 (2.3 mg/L), 10-epi-proansamitocin 8 (3.5 mg/L) and two
diastereomeric byproducts 9a and 9b (7.6 mg/L; 1:1 ratio) from
the fermentation broth of A. pretiosum Δasm12/21 (Figure 1).
We also showed that none of these proansamitocin derivatives
exhibit antiproliferative activity.
Herein, we describe the unprecedented formation of ansami-
tocin derivatives that are deoxygenated at C-7 of the ansami-
tocin core, obtained by us during fermentation experiments
using a variety of A. pretiosum mutants and mutasynthetic
approaches.
Results and Discussion
In the course of our well-established mutasynthesis experi-
ments with A. pretiosum HGF073, a mutant that is unable to
produce the essential starter unit AHBA (1) by itself, we
achieved the generation of several novel ansamitocin deriva-
tives, among other things, based on the simple mutasynthon
3-amino-5-chlorobenzoic acid (10, Scheme 2).
With the exception of proansamitocin analogue 11a, all new
metabolites were isolated on a preparative scale and fully char-
acterized. These compounds correspond to the known stepwise
sequence of postketide synthase tailoring transformations, and
those products and similar compounds have been reported by us
before [16]. As evident from the variety of compounds isolated,
proansamitocin analogues resulting from supplementation of
AHBA analogue 10 to A. pretiosum HGF073 were not effi-
ciently processed by the enzymes involved in post-PKS
tailoring. In addition to the ordinary compounds 11a–e, the
experiment yielded three compounds of an unprecedented type
(11f–h) whose appearance could not be attributed to the known
tailoring transformations. Herein, we now describe for the first
time the isolation and characterization of compounds 11f–h
sharing, in contrast to all other (pro)ansamitocin derivatives
known so far, the common feature of deoxygenation at C-7. In
addition, proansamitocin derivatives 11g–h are notable for their
C-9 alcohol, while 11h shows additional carbamoylation of the
unusual alcohol moiety. The extraordinary proansamitocin
derivatives 11f–h were fully characterized, except for the con-
figuration at C-9 in 11g and 11h (single diastereomer). Overlap
with other signals in the 1H NMR spectra hampered complete
assignment of all coupling constants at C-9 except for J9,10 =
7.2 Hz, which, however, is not diagnostic.
In continuation of our experiments with advanced biosynthetic
intermediates, such as proansamitocin (2) [25] and seco-acid
derivatives [26,27] serving as mutasynthons in experiments
with early-stage-blocked mutants, we also tested the unusual
metabolites 9a and 9b [17] as precursors for further processing
by the AHBA(−)-mutant of the ansamitocin producer
(Scheme 3).
Originally obtained by fermentation of a mutant blocked to the
greatest extent in the post-PKS transformation sequence
(A. pretiosum Δasm12/21) [17], it was questionable whether
these compounds, differing substantially from proansamitocin
(2) both by a rearranged diene system and an alcohol moiety at
C-14, would be accepted by the tailoring enzymes. Surprisingly,
when the rearranged oxidation products 9a and 9b were each
supplemented to cultures of A. pretiosum HGF073, new prod-
ucts were formed. While the carbamoylated derivative 12
resulting from biotransformation of alcohol 9b can be attrib-
uted to the activity of the carbamoyltransferase Asm21, thereby
providing an indication pertaining to its substrate flexibility,
products 13a and 13b obtained from both experiments are more
unusual and differ from the starting material by being deoxy-
genated at C-7.
However, the structure of compound 12 strongly contrasts with
all of the other 7-O-carbamoylated (pro)ansamitocin deriva-
tives that we have obtained with this kind of feeding experi-
ment so far [17]. In the case of compound 12, the carbinol-
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Scheme 2: Mutasynthetic preparation of ansamitocin derivatives 11a–h by using 3-amino-5-chlorobenzoic acid (10) as a mutasynthon (yields in %
are calculated with reference to the amount of mutasynthon 10 fed).
amide moiety is not present in a cyclic halfaminal form (δC-9
~197 ppm instead of ~82 ppm), despite the fact that the keto
group at C-9 is still present. This result may be attributed to the
keto group at C-9 being in conjugation with the diene system,
resulting in a reduced activity of the carbonyl group and an al-
teration of the macrolactam ring conformation.
We based the determination of deoxygenation at C-7 in 13a and
13b on MS data and the appearance of a secondary carbon atom
in exchange of the tertiary carbinol at C-7 on phase-sensitive
1H–13C-correlation NMR spectra (HSQC). It needs to be noted
that NOE-analysis combined with molecular modeling did not
allow elucidation of the absolute configuration at C-14 for the
new derivatives 13a and 13b, as it did not allow for the starting
compounds 9a and 9b [17].
In order to shed light on the sequence of events leading to
deoxygenation, the carbamoylated derivative 12 was again fed
to a culture of A. pretiosum HGF073, and the formation of new
products was analyzed by UPLC-HRMS of the partially puri-
fied crude extract (Scheme 3). Indeed, the expected deoxy-
genated product 13b could be detected, but was also accompa-
nied by the formation of alcohol 9b. Compound 9b may either
have resulted from Michael addition of water to the suspected
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Scheme 3: Mutasynthetic biotransformation of proansamitocin derivatives 9a and 9b with AHBA(−) mutant A. pretiosum HGF073 (starting materials
could be reisolated: 9a: 77% reisolated, 9b: 23% reisolated).
Scheme 4: Fermentation products 14–16 of acyl transferase Asm19-blocked mutant A. pretiosum HGF059 (Δasm19) (yields given as isolated prod-
uct per volume of fermentation broth).
intermediate enone 17 (see later in Scheme 5) or from
hydrolytic cleavage of the carbinolamide 12.
A blocked mutant of A. pretiosum that is unable to carry out
acylation of the C-3 alcohol of the carbamoylated proansami-
tocin derivative precursor due to genetic inactivation of the acyl
transferase Asm19, was reported by Floss et al. [21,28]. It was
known that mutant strain A. pretiosum HGF059 produces the
expected ansamitocin derivative 14 in good yield (Scheme 4)
[28]. Besides the ester side chain, compound 14 also lacks the
Beilstein J. Org. Chem. 2012, 8, 861–869.
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Scheme 5: Possible mechanism of deoxygenation at C-7 of proansamitocin derivatives.
epoxy functionality and the N-methyl group. These two
tailoring steps finalize the biosynthesis of ansamitocin P-3
(AP-3, 4) and occur only after acylation has taken place
(Scheme 1).
While examining the fermentation extract for byproducts we
were able to identify two new metabolites, 15 and 16. Forma-
tion of compound 15 can be traced back to inefficient chlorina-
tion, a phenomenon that we have encountered before in other
feeding experiments with proansamitocin [25]. More unusual is
metabolite 16, which is yet another example of a case in which
deoxygenation at C-7 has taken place.
In summary, deoxygenation may occur when the AHBA-
blocked mutant A. pretiosum HGF073 or the acyl transferase
Asm19-blocked mutant A. pretiosum HGF059 are employed,
whereas the reduction process does not occur with the blocked
mutant A. pretiosum ∆asm12/21. The major difference between
these three mutants is the presence (HGF073, HGF059) or
absence (Δasm12/21) of the carbamoyl transferase Asm21.
Carbamoylation of proansamitocin derivatives at C-7 (e.g. 11a,
9a/b and 7) introduces a fairly good leaving group β-positioned
to the keto group, thereby facilitating elimination to enones 17
(Scheme 5).
In the case of compound 12, which predominantly exists in a
form lacking the typical cyclized carbinolamide moiety, the C-9
keto group can preserve its electronic properties, thus facili-
tating the elimination step. Finally, the activity of a tailoring
reductase, which in all likelihood is not part of the PKS,
catalyzes the reduction of the α,β-unsaturated bond, yielding the
deoxygenated derivatives (11f, 13a/b, 16). Diastereoselective
reduction of the C-9 keto group and carbamoylation of inter-
mediate 11f would then result in compounds 11g and 11h, res-
pectively.
A factor contributing to the formation of deoxygenated
proansamitocin derivatives is likely the usage of the carbamoyl-
ated precursors by the Asm19 acyl transferase. Acylation is a
crucial bottleneck step in the otherwise partly flexible sequence
of post-PKS transformations. When this step cannot occur due
to the absence of an active acyl transferase (as in A. pretiosum
HGF059), or if the transformation is inefficient (e.g., com-
pound 11b) or even nonexistent due to an unusual substrate
(e.g., compound 12), carbamoylated intermediates accumulate.
Indeed, the carbamoylated product 11b was the major product
of the mutasynthesis experiment with mutasynthon 10. The
carbamoylated compounds may then be channeled into the
pathway leading to deoxygenated products. Depending on the
substrate, this process may be quite efficient. For instance, no
carbamoylated product could be isolated after the biotransfor-
mation of compound 9a, indicating an efficient transformation
of the suspected carbamoylated intermediate to the final prod-
uct 13a.
All (pro)ansamitocin derivatives fully characterized by NMR
were also subjected to in vitro biological testing with different
human cell lines derived from tumors or the umbilical vein. The
results from these tests are given as values for the half-maximal
inhibitory concentration of the respective ansamitocin deriva-
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Table 1: Antiproliferative activity IC50 [nmol/L] of 11c–e in comparison to AP-3 (4).a
compound
cell line
U-937 A-431 SK- OV-3 PC-3 MCF-7 HUVEC
AP-3 (4) 0.01 0.08 0.05 0.06 n.d. 0.02
11c 0.5 1.58 0.66 0.30 0.90 0.32
11d 0.05 0.10 0.05 0.16 0.11 0.08
11e 0.18 0.35 0.21 0.53 0.41 0.21
aValues shown are means of two determinations in parallel; human cell lines: U-937 (histiocytic lymphoma), A-431 (epidermoid carcinoma), SK-OV-3
(ovary adenocarcinoma), PC-3 (prostate adenocarcinoma), MCF-7 (breast adenocarcinoma), HUVEC (umbilical vein endothelial cells); n.d. = not
determined.
tives in comparison to the “gold standard” ansamitocin P-3 (4,
Table 1). As expected [14], all (pro)ansamitocin derivatives
lacking the ester side chain at C-3 (11b, 11g–h, 12–16) do not
show any antiproliferative activity (IC50 > 800 nM) for at least
two of the cell lines listed in Table 1.
Compounds 11c–e, bearing the ester side chain at C-3, predomi-
nantly showed activities in the pM range. As seen also with
AP-3 (4), there is no significant difference between cancerous
and healthy cells. The most active compound was the N-methyl
derivative 11d, which reached the activity of the standard AP-3
(4) for selected cell lines.
Conclusion
In conclusion, we disclose the isolation and chemical and
antiproliferative activity characterization of several novel
ansamitocin derivatives that are deoxygenated at C-7. We used
three different A. pretiosum mutants and a variety of mutasyn-
thetic approaches. These preliminary studies on the deoxygena-
tion at C-7 suggest that it occurs by elimination at C-7/C-8 after
carbamoylation has taken place, followed by reduction medi-
ated by an unknown reductase, which is not part of the main
assembly line PKS. As expected, all ansamitocin compounds
bearing the ester side chain at C-3 predominantly showed activ-
ities in the pM range.
Experimental
Analytical details are given in the Supporting Information
File 1.
Cultivation
In general, cultivation of microbial strains on agar plates was
conducted in a Heraeus incubator at 30 °C, while cultivation in
a shake flask was performed in a multilevel New Brunswick
Scientific Innova 4900 gyratory multi-shaker at 200 rpm at
29 °C.
Unless otherwise noted, the cultivation media were prepared
using distilled water and sterilized by autoclaving: YMG
medium – 10 g/L malt extract (Sigma), 4 g/L yeast extract
(Bacto), 4 g/L D(+)- glucose∙H2O; YMG agar – YMG medium
plus 22 g/L agar (Bacto); K-medium [29], basal composition
(final start concentration in the main culture corresponds to 5/6
of the values given for this medium due to dilution) – 60 g/L
dextrin from maize starch (Fluka), 30 g/L D(+)-maltose∙H2O
(Fluka), 5.25 g/L cottonseed flour (Proflo), 5 g/L CaCO3,
4.5 g/L yeast extract (Bacto), 300 mg/L K2HPO4 (Fluka, Trace-
Select), 2 mg/L FeSO4∙7H2O. K-medium, additive – auto-
claved and added separately: 3 g/L L-valine (final start concen-
tration in the main culture, from a 3% (w/v) stock solution).
A. pretiosum HGF073 is a replicate of strain HGF056 reported
in [22].
Fermentation of A. pretiosum strains
A. pretiosum strains (HGF073, HGF059, Δasm12/21) were
stored as spore suspensions in 40% (v/v) glycerol/water at
−80 °C, and used for the inoculation of YMG agar plates.
Following incubation of the plates for 4 d at 30 °C, 5–8 well-
sporulated colonies were transferred to a 1.5 mL tube charged
with 1 mL of sterile distilled water and filled to approx. 50%
height with sterile glass beads (Ø = 2 mm, washed with dilute
hydrochloric acid). After vortex-mixing, the resulting suspen-
sion was used for the inoculation of precultures in bottom-
baffled 250 mL Erlenmeyer flasks charged with YMG medium
(50 mL per flask, with additional steel spring). Precultures were
shaken for 2 d at 29 °C before inoculation of main production
cultures (1/15 dilution). Cultivations were performed in
K-medium with additives – 42 mL K-medium with L-valine,
3 mL preculture and one drop of SAG 471 anti-foam (GE Bayer
Silicones) [30] – by using nonbaffled 250 mL Erlenmeyer
flasks (final volume: 35–60 mL per flask, with additional steel
spring). Shaking was continued at 29 °C for a total cultivation
time of 7–10 days.
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For detection of novel products from test cultures, samples of
the culture broth (200 μL) were mixed with ethanol (200 μL),
centrifuged (20800g, 3 min, 4 °C) and the clear supernatant
subjected to UPLC-ESIMS analysis. Failing detection of novel
products, the culture broth was extracted three times with ethyl
acetate, dried over MgSO4, concentrated in vacuo, and filtered
over silica gel with ethyl acetate, and the solvent was removed
in vacuo. The residue was dissolved in methanol (1 mL) and
subjected to UPLC-ESIMS analysis.
For isolation of novel products from (large-scale) fermentations,
the combined fermentation broth was extracted with ethyl
acetate as described above, and the crude extract subjected to a
sequence of chromatographic purifications (Supporting Infor-
mation File 1).
Mutasynthesis with A. pretiosum HGF073
In mutasynthesis experiments with A. pretiosum HGF073,
production cultures were shaken for 2 d after inoculation (see
above) before mutasynthons were added (9a, 9b, 10 or 12). For
novel mutasynthons, productivity of the strain was first moni-
tored by parallel feeding of mutasynthons for which acceptance
was known (e.g., the natural starter building block: 3-Amino-5-
hydroxybenzoic acid, hydrochloride salt (1)). Mutasynthons
were dissolved in DMSO/water [preferably 1:1; volume of
feeding solution not exceeding 10% (v/v) with respect to the
recipient culture] and sterilized by filtration.
Mutasynthon 10 (1.25 mmol/L of fermentation broth) was
added to production cultures with a combined volume of
945 mL continuously (drop-wise) over the time-course of 3.5 d,
by using autoclavable, syringe pump-driven feeding capillaries
– Braintree Scientific BS-9000-8 syringe pump with Upchurch
Scientific high-purity Teflon® PFA tubing (1/16” OD, 0.1” ID)
and Tefzel® connectors.
Biotransformation of the proansamitocin derivatives 9a, 9b and
12 was carried out by supplementing a production culture of
A. pretiosum HGF073 (45 mL final volume; K-medium; see
above) with the respective derivative [9a/b (each: 4.5 mg,
9.8 µmol, dissolved in 2 mL DMSO:H2O = 1:1); 12 (0.1 mg,
0.2 µmol, dissolved in 1 mL DMSO)] in a single portion after
2.5 (for 12) to 3.5 d (for 9a/b) of shaking.
Following biotransformation (refermentation) of proansami-
tocin derivative 12, only UPLC-ESIMS analysis of the silica-
gel-filtered ethyl acetate extract taken up in methanol (see
above) was carried out. The retention times and mass spectra of
the detected product derivatives 9b and 13b were identical to
those of the previously isolated materials (Supporting Informa-
tion File 1).
Supporting Information
The supporting information provides purification protocols
of fermentations, a short description of the cell proliferation
assay, analytical descriptions of new metabolites and copies
of 1H and 13C NMR spectra.
Supporting Information File 1
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